300702SZSE
🚨 Material Event

Announcement Regarding the Proposed Selection of Wholly-Owned Subsidiary Products in the 12th National Centralized Drug Procurement

✨ AI Summary

Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., has been selected in the 12th national centralized drug procurement program. The selected products are Trazodone Hydrochloride Tablets and Edoxaban Tosylate Tablets. This selection is expected to increase sales volume and market share for these products, though the final procurement contracts remain subject to execution and implementation.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300702 Stock Abbreviation: Tianyu Shares Announcement No.: 2026-067

Zhejiang Tianyu Pharmaceutical Co., Ltd.

Announcement Regarding the Proposed Selection of Wholly-Owned Subsidiary Products in the 12th National Centralized Drug Procurement

Zhejiang Tianyu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") and its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., participated in the 12th national centralized drug procurement bidding organized by the Joint Procurement Office (hereinafter referred to as the "JPO"). According to the "Publicity of Proposed Selection Results for the 12th National Centralized Drug Procurement" released by the JPO on July 31, 2026, on the Shanghai Sunshine Medical Procurement Network (https://www.smpaa.cn), the Company's products, Trazodone Hydrochloride Tablets and Edoxaban Tosylate Tablets, have been proposed for selection in this centralized procurement. The relevant details are announced as follows:

I. Basic Information of Proposed Selected Products

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.